By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biomodels said today that Swedish Orphan Biovitrum has contracted it to test the possibility of developing a predictive assay to determine which stem cell therapy patients may be at risk for a complication called oral mucositis.

Under the agreement, the Watertown, Mass.-based preclinical drug research firm aims to develop a screening platform to define mucositis risk for patients undergoing conditioning regimens for hematopoietic stem cell transplants (HSCT).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.